<DOC>
	<DOCNO>NCT02296567</DOCNO>
	<brief_summary>To demonstrate effect Lucentis ( ranibizumab ) , Avastin ( bevacizumab ) , Eylea ( aflibercept ) level naturally occur Vascular Endothelial Growth Factor ( VEGF ) systemic circulation Age Related Macular Degeneration patient currently treat medication .</brief_summary>
	<brief_title>Comparison Pharmacokinetics Effect Systemic VEGF Levels Age Related Macular Degeneration Patients</brief_title>
	<detailed_description>To determine plasma level VEGF serum Pharmacokinetic ( PK ) level vary lengths time follow intravitreal injection Avastin , Lucentis , Eylea exudative macular degeneration . Patients test follow normal course treatment institute . All screening test conduct three study visit .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>1 . Ability provide write informed consent participation study . 2 . Adults â‰¥ 50 year age exudative macular degeneration treat Avastin , Lucentis , Eylea previously determine time interval exclusive single antiVEGF treatment type three month . 3 . CONTROL GROUP : Age match control group previously diagnose exudative macular degeneration also enrol . 4 . Provide sign informed consent . 1 . Uncontrolled blood pressure ( define systolic &gt; 160mm Hg Diastolic &gt; 95mm Hg patient sit ) 2 . Uncontrolled diabetes mellitus define Hemoglobin A1c ( HbA1C &gt; 12 % screening ) 3 . Concomitant ocular systemic administration drug may interfere potentiate mechanism action antiVEGF medication . 4 . Previous administration systemic antiangiogenic medication within 3 month 5 . Participation simultaneous medical investigation trial . 6 . Treatment within 2 month antiVEGF agent fellow eye anticipate need treatment study . 7 . Patients cancer diagnosis remission less five year exception patient skin cancer , basal cell squamous cell , treat exclusively topical treatment allow . 8 . Female patient reach menopause , define cessation menses minimum twelve month perimenopausal symptom . 9 . Patients significant wound heal trial . 10 . Patients history vitrectomy study eye . 11. patient uncontrolled psoriasis , rheumatoid arthritis , osteoarthritis .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>